DOJ Officially Reschedules Cannabis to Schedule III Under Trump Order
Federal cannabis rescheduling becomes reality as DOJ implements Schedule III classification, opening tax relief and research pathways for industry.
The Department of Justice has officially rescheduled cannabis from Schedule I to Schedule III of the Controlled Substances Act, marking the first major federal cannabis policy reform in over five decades. Acting Attorney General Todd Blanche signed the order implementing the reclassification, following President Trump's executive directive issued four months earlier. The move fundamentally alters the federal legal framework surrounding cannabis operations and research.
The rescheduling delivers immediate financial benefits to cannabis operators through Section 280E tax relief. Multi-state operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) have collectively paid hundreds of millions in additional federal taxes due to the prohibition on standard business deductions under Schedule I classification. Industry analysts estimate the tax savings could boost sector-wide EBITDA margins by 15-25 percentage points.
Schedule III status also removes significant barriers to cannabis research that have constrained scientific advancement and product development. Universities and research institutions can now conduct studies without navigating the complex DEA licensing requirements that previously limited investigations to a handful of federally-approved facilities. This regulatory shift accelerates clinical trials for medical cannabis applications and pharmaceutical development programs.
The rescheduling stops short of full federal legalization, maintaining cannabis as a controlled substance requiring DEA oversight for manufacturing and distribution. Interstate commerce remains restricted, preserving the state-licensed market structure that has defined the industry's growth trajectory. Banking regulations under the Controlled Substances Act continue to limit traditional financial services access for cannabis operators.
Equity markets have anticipated this regulatory milestone, with the AdvisorShares Pure US Cannabis ETF (MSOS) gaining over 40% since Trump's initial executive order. The rescheduling validates the investment thesis around federal policy normalization while setting the stage for potential broader reforms. Cannabis companies trading on Canadian exchanges may pursue US listings more aggressively as federal compliance barriers diminish, potentially expanding institutional investor participation in the sector.